top of page
Search

Insulet: New product cycle

  • Writer: Abacus Research
    Abacus Research
  • Sep 17, 2024
  • 1 min read

Insulet is a ~$17b market cap insulin pump leader.

  1. The primary bet is the Omnipod 5 driven product cycle:The approvals / product launches are mostly done, it is now just a question of execution and market demand.

  2. Insulet’s has seen significant devaluation on the back of GLP-1s.

    • The secondary bet is that the ‘negative’ impact of GLP-1s is negligible over the next decade. If this is proven, the multiple should expand

    • Note that GLP1s have no impact on type 1 diabetes, insulet’s core customer.


In our upside scenario we see a path to $3.6bn in 2027 revenues (2023-27 CAGR of 21%) and an EPS of $6.50 (25% CAGR), with EPS ~10% above consensus.


Potential Upside:     $320 (+37%)

Sensible Downside: $195(-16%)


 
 
 

Recent Posts

See All
Axon:

Axon is shifting from selling individual tools to providing an interconnected ecosystem. Hardware like TASERs and cameras now act as "data generators" that feed directly into high-margin software modu

 
 
 
C.H. Robinson

CHRW has been going through significant change, They are retaking market share. The new CEO has transformed the company by bringing in a lean / AI, that has helped CHRW to grow earnings despite strugg

 
 
 
Brookfield (BN):

We initially wrote up BN in Jan 2024, it has increased 70%, so why mention it again? Firstly, we think the fundamentals are as good now as they were 2 yrs ago, with a >15% IRR on offer. BN is not a we

 
 
 

Comments

bottom of page